Home
About Us
Membership
Member Biography

Member Biography

Tarah Ballinger, MD

Tarah Ballinger, M.D.

Phone: (317) 944-0920, Patient issues/appointments

Faculty appointments

Vera Bradley Foundation Scholar in Breast Cancer Research
Associate Professor of Clinical Medicine, Department of Medicine, Division of Hematology/Oncology, IU School of Medicine
Full member, Cancer Prevention and Control

My overarching research goal is to better understand the relationship between body composition, specifically bone and lean and fat tissue, with cancer incidence, outcomes, and side effects of cancer directed therapies, with a focus on breast cancer survivors. In particular, while a large organ system, muscle tissue is relatively underexplored in the pathogenesis of breast cancer and is affected by a large portion of our current therapies.

Effect of Rycals (ARM210) on aromatase inhibitor associated muscle weaknessIUSCC-0631

A study evaluating the pregnancy outcomes and safety of interrupting endocrine therapy for young women with endocrine responsive breast cancer who desire pregnancy(POSITIVE)A221405/IBCSG48-POSITIVE

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy.S1418/BR006

A Phase 2 Study of Neratinib with or without Fulvestrant in HER2-Positive, ER-Positive Metastatic Breast Cancer17-318

A quality improvement project to increase knowledge and referrals to the IU breast cancer prevention programCTO-IUSCC-0718

Phase 1a/1b Trial of Exercise Treatment with Concurrent First-Line Therapy for Hormone Receptor Positive Metastatic Breast CancerCTO-TBCRC054

Exercise in Metastatic Breast cancer: EMBodyCTO-IUSCCC-0781

A pilot study examining molecular and clinical effects of aromatase inhibitor therapy on skeletal muscle function in early stage breast cancerIUSCC-0647

CLUSTER RANDOMIZED CONTROLLED TRIAL OF PATIENT AND PROVIDER DECISION SUPPORT TO INCREASE CHEMOPREVENTION INFORMED CHOICE AMONG WOMEN WITH ATYPICAL HYPERPLASIA OR LOBULAR CARCINOMA IN SITU - MAKING INFORMED CHOICES ON INCORPORATING CHEMOPREVENTION INTO CARE (MiCHOICE)CTO-SWOG-S1904

Understanding and Predicting Breast Cancer Events After TreatmentWF-97415

Assessing Exercise Behavior and Preferences Among Patients and Oncologists at Indiana University Simon Cancer CenterIUSCC-0690

A single arm phase II study of ADjuvant Endocrine therapy, subcutaneous Pertuzumab, and Trastuzumab fixed-dose combination for patients with anatomic stage I hormone receptor-positive, HER2-positive breast cancer (ADEPT) CTO-20-347

Identifying gaps in breast cancer interception for high-risk women within IU HealthCTO-IUSCCC-0818

Examining Genetic Ancestry, Allostatic Load and Treatment Completion among Patients with Breast CancerCTO-2022C0174

COGNITIVE TRAINING FOR CANCER RELATED COGNITIVE IMPAIRMENT IN BREAST CANCER SURVIVORS: A MULTI-CENTER RANDOMIZED DOUBLE- BLINDED CONTROLLED TRIALCTO-NRG-CC011

NearWave optical molecular monitoring for predicting complete pathological response (pCR) to neoadjuvant chemotherapy (NAC) in breast cancer patients CTO-IUSCCC-0880

Addressing Food Insecurity Amongst Breast Cancer Patients Facing Food Insecurity in Central Indiana Through a Fresh Produce Delivery Service IUSCCC-0884

Understanding the Perception and Perceived Barriers of Participating in an Exercise Intervention in Women Living with Metastatic Breast CancerCTO-IUSCCC-0879

Exercise as Maintenance Therapy in Advanced Lung CancerCTO-IUSCCC-0865

A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score ≤ 25 (OFSET)CTO-NRG-BR009

Implementing cascade risk assessment in Black families affected by breast cancer CTO-IUSCCC-0855

EXAMINING THE ROLE OF ALLOSTATIC LOAD IN RACIAL DISPARITIES IN INTRINSIC BREAST CANCER SUBTYPE AND AS A PROGNOSTIC MARKERCTO-2023C0120

Exercise Habit for Breast Cancer Risk Reduction- A Randomized Clinical Trial: EXTENSION Study CTO-IUSCCC-0861

A Randomized Phase III Trial Comparing Active Symptom Monitoring Plus Patient Education Versus Patient Education Alone To Improve Persistence With Endocrine Therapy In Young Women With Stage I-III Breast Cancer (ASPEN)CTO-S2010

A Randomized Phase III Trial of Olanzapine Versus Megestrol Acetate for Cancer-Associated AnorexiaCTO-A222004

Physical activity promotion among cancer patients HEMO-BSU-2197179

Headlines & highlights

Simon Says Expert Series featuring Tarah Ballinger

Esophageal Cancer Awareness: Gastroesophageal Reflux, Cancer & More

April 2023

Get a Move on Cancer: Impact of Physical Activity in Prevention, Treatment and Survivorship

September 2021

#ResearchCuresCancer

Support Our Research